eIF2β, a subunit of translation‐initiation factor EIF2, is a potential therapeutic target for non‐small cell lung cancer

To identify novel therapeutic targets for non‐small cell lung cancer (NSCLC), we conducted an integrative study in the following 3 stages: (i) identification of potential target gene(s) through shRNA functional screens in 2 independent NSCLC cell lines; (ii) validation of the clinical relevance of identified gene(s) using public databases; and (iii) investigation of therapeutic potential of targeting the identified gene(s) in vitro. A semi‐genome‐wide shRNA screen was performed in NCI‐H358 cells, and was integrated with data from our previous screen in NCI‐H460 cells. Among genes identified in shRNA screens, 24 were present in both NCI‐H358 and NCI‐H460 cells and were considered potential targets. Among the genes, we focused on eIF2β, which is a subunit of heterotrimeric G protein EIF2 and functions as a transcription initiation factor. The eIF2β protein is highly expressed in lung cancer cell lines compared with normal bronchial epithelial cells, and gene copy number analyses revealed that eIF2β is amplified in a subset of NSCLC cell lines. Gene expression analysis using The Cancer Genome Atlas (TCGA) dataset revealed that eIF2β expression is significantly upregulated in lung cancer tissues compared with corresponding normal lung tissues. Furthermore, high eIF2β expression was correlated with poor survival in patients with lung adenocarcinoma, as shown in other cohorts using publicly available online tools. RNAi‐mediated depletion of eIF2β suppresses growth of lung cancer cells independently of p53 mutation status, in part through G1 cell cycle arrest. Our data suggest that eIF2β is a therapeutic target for lung cancer.

[1]  N. Setterblad,et al.  Deletion of eIF2β lysine stretches creates a dominant negative that affects the translation and proliferation in human cell line: A tool for arresting the cell growth , 2017, Cancer biology & therapy.

[2]  K. Coombes,et al.  Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer , 2017, Cancer science.

[3]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[4]  R. Morgan,et al.  Ran GTPase promotes cancer progression via Met receptor-mediated downstream signaling , 2016, Oncotarget.

[5]  John D. Minna,et al.  XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer , 2016, Nature.

[6]  T. Umehara,et al.  Crystal structure of eukaryotic translation initiation factor 2B , 2016, Nature.

[7]  David Petersen,et al.  An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  A. Koromilas Roles of the translation initiation factor eIF2α serine 51 phosphorylation in cancer formation and treatment. , 2015, Biochimica et biophysica acta.

[9]  Nobhojit Roy,et al.  The Global Burden of Cancer 2013. , 2015, JAMA oncology.

[10]  Michael L. Gatza,et al.  An integrated genomics approach identifies drivers of proliferation in luminal subtype human breast cancer , 2014, Nature Genetics.

[11]  Kwok-Kin Wong,et al.  Non-small-cell lung cancers: a heterogeneous set of diseases , 2014, Nature Reviews Cancer.

[12]  John D. Minna,et al.  Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations , 2013, Molecular Cancer Research.

[13]  Sanjeev Gupta,et al.  The eIF2α kinases: their structures and functions , 2013, Cellular and Molecular Life Sciences.

[14]  Osama Sharaf Eldin,et al.  Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways , 2011, Clinical Cancer Research.

[15]  Jian-Ting Zhang,et al.  Translational control gone awry: a new mechanism of tumorigenesis and novel targets of cancer treatments. , 2011, Bioscience reports.

[16]  Jason D. Heaney,et al.  Deletion of eIF2beta suppresses testicular cancer incidence and causes recessive lethality in agouti-yellow mice. , 2009, Human molecular genetics.

[17]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[18]  J. Minna,et al.  A Translational View of the Molecular Pathogenesis of Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Xiaomei Ma,et al.  Global Burden of Cancer , 2006, The Yale journal of biology and medicine.

[20]  J. Minna,et al.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.

[21]  J. Pollack,et al.  Immortalization of Human Bronchial Epithelial Cells in the Absence of Viral Oncoproteins , 2004, Cancer Research.

[22]  A. Fraire,et al.  Expression of eukaryotic translation initiation factors 4E and 2α is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung , 2001, Cancer.

[23]  A. Jemal,et al.  Lung Cancer Statistics. , 2016, Advances in experimental medicine and biology.

[24]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.